For columnist Sam Kirton, Pulmonary Fibrosis Awareness Month is an opportunity to tell others about his journey.

GRI-0621, an experimental oral therapy for IPF, may stabilize lung function, according to an interim analysis of an ongoing ...

As she plans her return to university teaching, columnist Ann Reynoso realizes how PF has given her a range of new skills for ...

Using a specialized lab technique, scientists identified early cellular changes that may help drive lung scarring in ...

Columnist Sam Kirton thought he'd meticulously prepared for his vacation, with all his medications in store. Then an illness took him down.

An experimental oral therapy for idiopathic pulmonary fibrosis (IPF) has been tolerated well in an ongoing Phase 2 clinical trial, according to interim data announced by its developer GRI Bio. “We are ...

Taking oral dietary supplements of epigallocatechin-3-gallate (EGCG) — an antioxidant in green tea — may stop and reverse the pro-fibrotic (scarring) state of the lungs of people with idiopathic ...

Endeavor BioMedicines’ ENV-101 improved lung function and reversed key signs of lung scarring in people with idiopathic pulmonary fibrosis (IPF), according to data from a completed Phase 2a trial. The ...

It’s been hotter than usual here in the mid-Atlantic. Temperatures in the upper 90s, flirting with 100 F, plus high humidity made it feel like 107 to 115 F. If I had to sum it up in a single word, I’d ...

A Phase 3 clinical trial testing Boehringer Ingelheim’s oral investigational treatment nerandomilast in people with idiopathic pulmonary fibrosis (IPF) has met its primary goal of demonstrating the ...

The National Institutes of Health has awarded $219,000 to fund a project at the University of Texas at Tyler aimed at developing a treatment for radiation-induced pulmonary fibrosis (PF) which can ...